Search The Medical Knowledge Base

Drug Details

ADCAL-D3 Dissolve

• Drug Class Description
  Calcium supplements / vitamin D3 .
• Generic Name
  Calcium carbonate, vitamin D - osteoporosis 3
• Presentation
  White, round, lemon flavoured effervescent tablets.
• Description
  One effervescent tablet contains: 1500 mg calcium carbonate (equivalent to 600 mg or 15 mmol elemental calcium) 400 I.U. or 10 micrograms colecalciferol (vitamin D3) as colecalciferol concentrate 'powder form' This product also contains sucrose (part of the vitamin D3 concentrate: approximately 1.5 micrograms per tablet) and soya oil (also part of the vitamin D3 concentrate: approximately 0.3 milligrams per tablet).
• Indications
  As an adjunct to specific therapy for osteoporosis and in situations requiring therapeutic supplementation of malnutrition e.g. in pregnancy and established vitamin D dependent osteomalacia. The prevention and treatment of calcium deficiency/vitamin D deficiency especially in the housebound and institutionalised elderly subjects. Deficiency of the active moieties is indicated by raised levels of PTH, lowered 25-hydroxy vitamin D and raised alkaline phosphatase levels which are associated with increased bone loss.
• Adult Dosage
  

  Oral.

  Adults and elderly and children over 12 years of age:	Take 2 effervescent tablets daily, preferably one tablet each morning and evening.
  	The effervescent tablets should be dissolved in a glass of water (approx. 200ml) and drunk immediately
  Children:	Not recommended for children under 12 years.

• Child Dosage
  Not recommended.
• Contra Indications
  

  Absolute contra-indications are hypercalcaemia resulting for example from myeloma, bone metastases or other malignant bone disease, sarcoidosis; primary hyperparathyroidism and vitamin D overdosage. Severe renal failure. Hypersensitivity to any of the tablet excipients.

  Relative contra-indications are osteoporosis due to prolonged immobilisation, renal stones, severe hypercalciuria.

  Adcal-D₃ Dissolve contains a small quantity of soya oil and is therefore contraindicated in patients who are allergic to peanuts or soya.

• Special Precautions
  

  Patients with mild to moderate renal failure or mild hypercalciuria should be supervised carefully including periodic checks of plasma calcium levels and urinary calcium excretion.

  In patients with a history of renal stones urinary calcium excretion should be measured to exclude hypercalciuria.

  With long-term treatment it is advisable to monitor serum and urinary calcium levels and kidney function, and reduce or stop treatment temporarily if urinary calcium exceeds 7.5mmol/24 hours (300mg/24 hours).

  Caution is required in patients receiving treatment for cardiovascular disease.

  Adcal-D₃ Dissolve should also be used with caution in other patients with increased risk of hypercalcaemia e.g. patients with sarcoidosis or those suffering from malignancies.

  Patients with rare hereditary problems of fructose intolerance, glucose-galactose malabsorption or sucrase-isomaltase insuffiency should not take this medicine.

  Allowances should be made for calcium and vitamin D supplements from other sources.

  Information for diabetics :

  Patients who have diabetes mellitus or require a low-sugar diet should take account of the sucrose content of this medicinal product.

  One effervescent tablet contains 1.672mg of sucrose.

• Interactions
  

  The risk of hypercalcaemia should be considered in patients taking thiazide diuretics since these drugs can reduce urinary calcium excretion. Hypercalcaemia must be avoided in digitalised patients.

  Certain foods (e.g. those containing oxalic acid, phosphate or phytinic acid) may reduce the absorption of calcium.

  Concomitant treatment with phenytoin or barbiturates can decrease the effect of vitamin D because of metabolic activation. Concomitant use of glucocorticoids can decrease the effect of vitamin D.

  The effects of digitalis and other cardiac glycosides may be accentuated with the oral administration of calcium combined with vitamin D. Strict medical supervision is needed and, if necessary monitoring of ECG and calcium.

  Calcium salts may reduce the absorption of thyroxine, bisphosphonates, sodium fluoride, quinolone or tetracycline antibiotics or iron. It is advisable to allow a minimum period of four hours before taking the calcium.

• Adverse Drug Reactions
  

  The use of calcium supplements has, rarely, given rise to mild gastro-intestinal disturbances, such as constipation, flatulence, nausea, gastric pain, diarrhoea. Following administration of vitamin D supplements occasional skin rash has been reported. Hypercalciuria, and in rare cases, hypercalcaemia have been seen with long term treatment at high dosages.